Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN® in patients with Sickle Cell Disorder
References (12)
- et al.
Acute and Short term toxicity of NIPRISAN® in rats. I: biochemical study
J. Pharm. Res. and Dev.
(1996) - Clinical Alert National Heart, Lung and Blood Institute, NIH. 13:26; 003. 10, Feb...
Sickle Cell Disease in Childhood
- et al.
Renal Function
- et al.
Pharmacological Profile of NIPRD 94/002/1–0: A Novel Herbal Antisickling Agent
J. Pharm. Res. And Dev.
(1998)
Cited by (80)
Prevalence of Use of Herbal Medicines for the Treatment of Sickle Cell Disease in Africa: a Systematic Review and Meta-analysis
2023, Journal of Herbal MedicineFunctional foods: promising therapeutics for Nigerian Children with sickle cell diseases
2022, HeliyonCitation Excerpt :Eugenia caryophyllata and Piper guineense are other examples of medicinal plants thatcontain vanilloids like Shikimic acid and cannaboids that are of benefit in reducing the painful symptoms of SCD [126]. Additional phytomedicines that have been reported to possess antisickling potentials are Pterocarpa osun, Justicia secunda, and Sorghum bicolor extracts [127,128]. Taken together, these functional foods can be used in the form of food or decoction.
Time for African youth in science
2022, Acta TropicaCitation Excerpt :In Togo, people use DREPANOSTAT® (also a mixture of Z. zanthoxyloïdes and C. procera) against the sickle cell anemia (Villaret et al., 2018). In Nigeria, the treatment proposed is NIPRISAN® (Piper guineenses seeds, Pterocarpus osun stem, Eugenia caryophylum fruit and Sorghum bicolor leaves) (Wambebe, 2001). Formulation can be performed in Africa with companies such as the Nigerian pharmaceutical company May & Bake which formulates the NIPRISAN®.
A highly sensitive UPLC-MS/MS method for hydroxyurea to assess pharmacokinetic intervention by phytotherapeutics in rats
2020, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :In this direction, plants based natural products, including amino acids for adjuvant/supplementation therapy, have been explored in the preclinical/clinical model to elucidate their beneficial role for the symptomatic management of SCA. Representative examples of such phytochemical/botanical drug are L-arginine [9], caricapinoside [10], resveratrol [11], curcumin [12], docosahexaenoic acid/omega-3 fatty acid [13], gum arabic [14], SCD-101 [15], NIPRISAN [16], and so on. Therefore, we would like to identify phytochemicals that can’t hinder the pharmacokinetics of HU and at the same time those compounds have the useful pharmacological effects to combat with the side effects associated with HU therapy.
Advances in the Treatment of Sickle Cell Disease
2018, Mayo Clinic ProceedingsCitation Excerpt :Part B of this phase 1b clinical trial is a randomized, double blind, placebo-controlled crossover study of SCD-101 in patients with SCA and is currently recruiting (NCT02380079). Another antisickling agent with an unknown mechanism of action, Nicosan (or Niprisan) is a plant extract shown to decrease painful crises in Nigerian patients.63,64 There are no trials studying Niprisan in the United States.
Treating sickle cell disease by targeting HbS polymerization
2017, BloodCitation Excerpt :Among the drugs listed as antisickling agents is SCD-101, a plant extract similar to Niprisan (Nix-0699). Niprisan is an ethanol-water extract from the seeds, stems, fruit, and leaves of 4 different plants, has been used among diverse populations in Nigeria, and has been reported to be effective in lowering the frequency of pain crises in sickle cell patients.97,98 Niprisan inhibits in vitro sickling and increases both the solubility and delay time of solutions of deoxy-HbS, albeit in a highly nonphysiological buffer.99